Business
The announcement comes the same week the pharma giant ended its collaboration with Hims & Hers to sell Wegovy, alleging the company engages in deceptive marketing and illegally sells copycat drugs.
HIMSS25
Penn Medicine's Anna Schoenbaum says the HIMSS Nursing Innovation Advisory Workgroup, which she co-chairs, has developed AI toolkits and customizable teaching slides to help leaders understand AI's complexity, costs and impact.
Christopher McGhee says that, along with the acquisition, Current Health will have a "return to scrappiness and that startup spirit."
HIMSS25
Nicole Rogas, RevSpring president, says health systems can improve the billing experience and collect more revenue by using AI and data analytics to create personalized messages delivered via patients' preferred contact methods.
The company offers an AI-enabled workflow automation platform for administrative tasks pertaining to specialty medications.
The company will use the funds to hasten product development, engineering and go-to-market efforts to meet market demand.
The company will use the funds to invest in research and development and to scale its voice AI platform.
The company will use the funds to advance its AI-enabled robotic platform for cataract and other eye surgeries, with plans to begin human clinical trials this year.
The Series E funding comes four months after the company secured $250 million in a Series D round.
HIMSS25
AI tools can personalize patients' searches for providers, but Kyruus Health's Gen Conlin believes nurse informaticists' ability to ensure tool accessibility and accuracy are vital to ensuring patients find the right care.